RecruitingPhase 3NCT05601700

Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

Studying Adenocarcinoma of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ente Ospedaliero Ospedali Galliera
Principal Investigator
Andrea DeCensi, MD
E.O.Ospedali Galliera
Intervention
Letrozole tablets(drug)
Enrollment
132 enrolled
Eligibility
18 years · FEMALE
Timeline
20222029

Study locations (19)

Collaborators

Istituto Di Ricerche Farmacologiche Mario Negri · Humanitas Hospital, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05601700 on ClinicalTrials.gov

Other trials for Adenocarcinoma of ovary

Additional recruiting or active studies for the same condition.

See all trials for Adenocarcinoma of ovary

← Back to all trials